« Return to News | Drug Sponsors

Accu-Break, Alembic enter into product development and license agreement

Friday, August 10, 2012 11:02 AM

India-based Accu-Break Pharmaceuticals (ABP) has entered into a development and license agreement with Alembic Pharmaceuticals of Plantation, Fla., to develop new brand products that will use ABP’s innovative Accu-Break tablet technologies.

ABP’s patented Accu-Break tablets can be split easily by hand into exact smaller doses to provide maximum flexibility, and to make it easier and safer for patients and caregivers to adjust their dosage. The first product that ABP will seek FDA marketing approval for is an Accu-Break-formatted version of the popular anticoagulant medication warfarin (Coumadin).

“We are delighted to be working with a leading pharmaceutical company in India that is vertically integrated and has the ability and expertise to develop and manufacture pharmaceutical products for the U.S. market,” said Elliot F. Hahn, Ph.D., executive chairman of ABP. “Together, we are looking forward to filing the first of what we anticipate will be many 505(b)(2) New Drug Applications for products utilizing our patented Accu-Break technologies in combination with Alembic’s broad base of active pharmaceutical ingredients and formulations.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.